HSBC Holdings’s Black Diamond Therapeutics BDTX Stock Holding History

HSBC Holdings’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$56.8K	Hold	26,421	–	–	﹤0.01%	2796
2025 Q4	$66.8K	Hold	26,421	–	–	﹤0.01%	2837
2025 Q3	$97.8K	Sell	26,421 -15,278	-37%	-$44.7K	﹤0.01%	2599
2025 Q2	$99.5K	Buy	41,699 +14,570	+54%	+$28.1K	﹤0.01%	2855
2025 Q1	$42.3K	Sell	27,129 -30	-0.1%	-$63	﹤0.01%	2923
2024 Q4	$59.2K	Buy	27,159 +13,511	+99%	+$38.7K	﹤0.01%	2966
2024 Q3	$57.3K	Buy	+13,648	New	+$74.3K	﹤0.01%	2870
2023 Q3	–	Sell	-24,156	Closed	-$120K	–	2717
2023 Q2	$120K	Hold	24,156	–	–	﹤0.01%	2405
2023 Q1	$44.9K	Hold	24,156	–	–	﹤0.01%	2572
2022 Q4	$43.2K	Buy	24,156 +11	+0%	+$20	﹤0.01%	2976
2022 Q3	$41K	Sell	24,145 -1,891	-7%	-$5.83K	﹤0.01%	2835
2022 Q2	$64K	Hold	26,036	–	–	﹤0.01%	3107
2022 Q1	$72K	Hold	26,036	–	–	﹤0.01%	3168
2021 Q4	$143K	Buy	+26,036	New	+$182K	﹤0.01%	3098
2021 Q1	–	Sell	-8,518	Closed	-$274K	–	2740
2020 Q4	$274K	Buy	+8,518	New	+$280K	﹤0.01%	2623

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

HSBC Holdings's BDTX Position: Q1 2026 in Review

HSBC Holdings held its Black Diamond Therapeutics (BDTX) position steady in Q1 2026 at 26,421 shares worth $56.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2796.

HSBC Holdings first reported a position in BDTX in Q4 2020 and has held it in 15 quarters since. The position peaked at $274K in Q4 2020. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

HSBC Holdings held 26,421 shares of Black Diamond Therapeutics worth $56.8K as of Q1 2026.
HSBC Holdings left its Black Diamond Therapeutics share count unchanged in Q1 2026.
Black Diamond Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2796 holding.
HSBC Holdings first reported a position in Black Diamond Therapeutics in Q4 2020 and has held it in 15 quarters since.
HSBC Holdings's Black Diamond Therapeutics position peaked at $274K in Q4 2020.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.